Adjuvant Capital

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

InDevR, Inc. is a biotechnology company based in Boulder, Colorado, focused on developing and marketing life science instrumentation and assay products for the analysis of viruses and microorganisms. The company offers a range of products including the Virus Counter for virus quantification, the FluChip for rapid pathogen detection, and the ViroPrep Allantoic Influenza kit for sample preparation. Additionally, InDevR provides the miPLEX platform for multiplexed immunoassays, the Vidia fluorescence microarray imaging system, and the ampliPHOX Reader for image interpretation of microarrays. These innovative technologies support vaccine research, development, and manufacturing by facilitating the tracking of seasonal and emerging influenza viruses, as well as enhancing diagnostic applications in the life sciences industry. InDevR was incorporated in 2002.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

54gene is a healthcare company founded in 2019 by Dr. Abasi Ene-Obong, focused on advancing genomic research in Africa. Headquartered in San Francisco with an office in Lagos, Nigeria, the company aims to address the underrepresentation of African genetic data in pharmaceutical research, where only 2% of genetic material used is from African populations. By developing a pan-African biobank, 54gene seeks to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular, and neurodegenerative diseases. Additionally, the company offers genetic testing and molecular diagnostics services to enhance understanding of the human genome and improve access to essential healthcare solutions.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

54gene is a healthcare company founded in 2019 by Dr. Abasi Ene-Obong, focused on advancing genomic research in Africa. Headquartered in San Francisco with an office in Lagos, Nigeria, the company aims to address the underrepresentation of African genetic data in pharmaceutical research, where only 2% of genetic material used is from African populations. By developing a pan-African biobank, 54gene seeks to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular, and neurodegenerative diseases. Additionally, the company offers genetic testing and molecular diagnostics services to enhance understanding of the human genome and improve access to essential healthcare solutions.

VitriVax is a biotechnology startup based in Boulder, Colorado, focused on developing an innovative vaccine formulation platform. The company utilizes its proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology to create vaccines that are more effective, affordable, and accessible worldwide. This technology addresses the challenges associated with vaccine stability and administration by enabling the development of thermostable, single-shot vaccines that can effectively incorporate both prime and booster doses. VitriVax's advancements in vaccine formulation aim to eliminate barriers to global vaccination, ultimately enhancing immune responses for a broad range of medical indications. The company has received significant funding, including over $5 million from various sources such as the National Institutes of Health, the National Science Foundation, and the Bill and Melinda Gates Foundation, to support its mission.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company specializes in developing gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company is committed to advancing these therapeutics to ensure they are safe and effective, with the goal of significantly improving the lives of individuals affected by viral infections worldwide.

Frontier Nutrition, Inc. is a company that develops and manufactures fortified packaged food products aimed at addressing the nutritional needs of low and middle-income families in underserved communities worldwide. Founded in 2017 by Eddie Bearnot and Tanveer Ali, the company is headquartered in New Haven, Connecticut. Frontier Nutrition's offerings are informed by research in pediatric nutrition and behavioral marketing, ensuring that recipes are tailored to local diets while being optimized for taste, nutrition, and affordability. The company's mission is to combat early life and maternal malnutrition by providing low-cost, convenient food options to families facing challenges such as limited access to healthcare, transportation, and clean water, thereby promoting a sustainable standard of living.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.

54gene is a healthcare company founded in 2019 by Dr. Abasi Ene-Obong, focused on advancing genomic research in Africa. Headquartered in San Francisco with an office in Lagos, Nigeria, the company aims to address the underrepresentation of African genetic data in pharmaceutical research, where only 2% of genetic material used is from African populations. By developing a pan-African biobank, 54gene seeks to identify new drug targets and create diagnostics and treatments for various diseases, including cancer, cardiovascular, and neurodegenerative diseases. Additionally, the company offers genetic testing and molecular diagnostics services to enhance understanding of the human genome and improve access to essential healthcare solutions.

Codagenix, Inc. is a biotechnology company specializing in the development of live-attenuated viral vaccines targeting various diseases, including influenza, dengue, respiratory syncytial virus, and polio. Founded in 2009 and based in Farmingdale, New York, the company leverages its innovative Synthetic Attenuated Virus Engineering (SAVE) platform, which employs computer-based rational design to re-engineer the genomes of viruses. This technology enables the creation of vaccines that incorporate specific target antigens within an attenuated viral backbone. In addition to human vaccines, Codagenix also develops vaccines for agricultural and companion animals, contributing to a broader approach to viral disease management.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

InDevR, Inc. is a biotechnology company based in Boulder, Colorado, focused on developing and marketing life science instrumentation and assay products for the analysis of viruses and microorganisms. The company offers a range of products including the Virus Counter for virus quantification, the FluChip for rapid pathogen detection, and the ViroPrep Allantoic Influenza kit for sample preparation. Additionally, InDevR provides the miPLEX platform for multiplexed immunoassays, the Vidia fluorescence microarray imaging system, and the ampliPHOX Reader for image interpretation of microarrays. These innovative technologies support vaccine research, development, and manufacturing by facilitating the tracking of seasonal and emerging influenza viruses, as well as enhancing diagnostic applications in the life sciences industry. InDevR was incorporated in 2002.

X-Vax Technology is a biotechnology company based in Jupiter, Florida, established in 2015. The company specializes in the preclinical and clinical development of vaccines designed to combat mucosal infections caused by pathogens such as herpes, influenza, tuberculosis, and HIV, which impact millions globally. X-Vax is advancing a herpes vaccine candidate based on a genetically modified HSV-2 virus that lacks glycoprotein D. This innovative approach aims to prevent infections from both herpes type 1 and type 2 by inducing antibodies that facilitate antibody-dependent cell-mediated killing, thereby creating a robust immune response against these viruses.